A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benefit to participants.
Checked against the public recordLast updated Mar 18, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Bristol-Myers Squibb
- Interventions being studied
- Biological: BMS-986442; Biological: Nivolumab; Drug: Docetaxel; Drug: Carboplatin; Drug: Pemexetred; Drug: Paclitaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Participants in all parts of the study must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. * Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Participants must have a life expectancy of at least 3 months at the time of first dose. Exclusion Criteria: * Untreated symptomatic central nervous system metastases or leptomeningeal metastases. * Concurrent malignancy (present during screening) requiring treatment, or history of prior malignancy active within 2 years prior to randomization in study Part B1 or treatment assignment in all other study parts. * Participants with an active, known, or suspected autoimmune disease. Other protocol-defined inclusion/exclusion criteria apply.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Mayo Clinic in Arizona - PhoenixPhoenix, Arizona
- Local Institution - 0096Costa Mesa, California
- Local Institution - 0075Orange, California
- Mayo Clinic in FloridaJacksonville, Florida
- Local Institution - 0027Orlando, Florida
- Local Institution - 0029Fort Wayne, Indiana
- Local Institution - 0022New Orleans, Louisiana
- Local Institution - 0005Grand Rapids, Michigan
- Mayo Clinic in Rochester, MinnesotaRochester, Minnesota
- Local Institution - 0003Hackensack, New Jersey
- Carolina BioOncology InstituteHuntersville, North Carolina
- Local Institution - 0019Cincinnati, Ohio
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 18, 2025. Always confirm current availability with the study team.